secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001493152-25-017007
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImprimisRx (Harrow subsidiary) appoints Frank Mullery as CEO; prior CEO John Saharek transitions out
--------------------------------------------------------------------------------

- John Saharek ceased as President/CEO of ImprimisRx effective Oct 6, 2025; transitions to non-officer role with no new compensation.
- Frank Mullery appointed CEO of ImprimisRx; previously President of Sintetica US and led Mylan Institutional to >$1B revenue.
- Bridseida Cruz appointed Head of Quality; over 25 years experience in FDA remediation and operational improvement.
- No compensatory arrangements entered with Saharek in connection with transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225017007/0001493152-25-017007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225017007/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer